Compare LOAN & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOAN | GRML |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 51.5M |
| IPO Year | 1999 | 2022 |
| Metric | LOAN | GRML |
|---|---|---|
| Price | $4.43 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.2K | ★ 3.5M |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $8,666,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $0.21 |
| 52 Week High | $5.85 | $0.55 |
| Indicator | LOAN | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 36.76 |
| Support Level | $4.41 | N/A |
| Resistance Level | $4.48 | $0.34 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 86.96 | 34.70 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.